Paper39776249
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD and 15 others. Alzheimers Dement, 2025. Cited by 127 papers, by iCite.
Cite this record
ConductScience Library. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Papers, record 39776249. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39776249
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Amyloid | Major topic |
| Brain | Major topic |
| Molecular Imaging | Major topic |
| Positron-Emission Tomography | Major topic |
| tau Proteins | Major topic |
| Humans | |
| Nuclear Medicine | |
| Societies, Medical |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 40105389 | Beyond the AJR: Updated Guidelines on the Appropriate Use of Amyloid and Tau PET in Clinical Practice. | https://conductscience.org/library/papers/40105389 |
Source PubMed
References248
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28592453 | Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. | Neurology | 2017 | https://conductscience.org/library/papers/28592453 | PubMed |
| 2 | 29050382 | Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. | Brain | 2017 | https://conductscience.org/library/papers/29050382 | PubMed |
| 3 | 25824567 | Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. | Alzheimers Dement | 2015 | https://conductscience.org/library/papers/25824567 | PubMed |
| 4 | 31371569 | High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. | Neurology | 2019 | https://conductscience.org/library/papers/31371569 | PubMed |
| 5 | 30938796 | Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. | JAMA | 2019 | https://conductscience.org/library/papers/30938796 | PubMed |
| 6 | 33585983 | Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. | Acta Neuropathol | 2021 | https://conductscience.org/library/papers/33585983 | PubMed |
| 7 | 34083813 | Biomarkers for neurodegenerative diseases. | Nat Med | 2021 | https://conductscience.org/library/papers/34083813 | PubMed |
| 8 | 38048096 | Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. | JAMA Neurol | 2024 | https://conductscience.org/library/papers/38048096 | PubMed |
| 9 | 29653606 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29653606 | PubMed |
| 10 | 29114726 | Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. | JAMA Neurol | 2017 | https://conductscience.org/library/papers/29114726 | PubMed |
| 11 | 39776249 | Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/39776249 | PubMed |
| 12 | 29499171 | CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29499171 | PubMed |
| 13 | 22749065 | Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. | Lancet Neurol | 2012 | https://conductscience.org/library/papers/22749065 | PubMed |
| 14 | 30326496 | Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. | JAMA | 2018 | https://conductscience.org/library/papers/30326496 | PubMed |
| 15 | 29049582 | Elevated Brain Amyloid in Cognitively Normal Individuals-Reply. | JAMA | 2017 | https://conductscience.org/library/papers/29049582 | PubMed |
| 16 | 23166389 | Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. | J Nucl Med | 2013 | https://conductscience.org/library/papers/23166389 | PubMed |
| 17 | 34279544 | Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/34279544 | PubMed |
| 18 | 37421950 | Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies. | Cell | 2023 | https://conductscience.org/library/papers/37421950 | PubMed |
| 19 | 28259709 | Consensus classification of posterior cortical atrophy. | Alzheimers Dement | 2017 | https://conductscience.org/library/papers/28259709 | PubMed |
| 20 | 24798886 | A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. | Alzheimers Dement | 2014 | https://conductscience.org/library/papers/24798886 | PubMed |
Cited by100
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 127 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42880054 | Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease. | J Prev Alzheimers Dis | 2026 | https://conductscience.org/library/papers/42880054 | PubMed |
| 42877686 | Low-dose CT for MRI-free quantification of tau PET in Alzheimer's disease: a multicentre, cross-sectional, comparison study. | Lancet Med Imaging Theranostics | 2026 | https://conductscience.org/library/papers/42877686 | PubMed |
| 42877495 | Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey. | J Alzheimers Dis Rep | 2026 | https://conductscience.org/library/papers/42877495 | PubMed |
| 42769842 | Exercise timing as a potential temporal regulator of neurolymphatic physiology in neurodegenerative proteinopathies: a mechanistic framework. | Front Neurosci | 2026 | https://conductscience.org/library/papers/42769842 | PubMed |
| 42760345 | Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/42760345 | PubMed |
| 42742914 | From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer's Disease. | CNS Drugs | 2026 | https://conductscience.org/library/papers/42742914 | PubMed |
| 42720909 | Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42720909 | PubMed |
| 42683384 | From amyloid PET to plasma biomarkers: A multimodal imaging framework for early diagnosis and staging of Alzheimer's disease. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42683384 | PubMed |
| 42661000 | Prognostic value of Amyloid PET in Real-World Amnestic MCI: Influence of reader experience and interpretation method. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42661000 | PubMed |
| 42643714 | Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer's disease. | Front Neurol | 2026 | https://conductscience.org/library/papers/42643714 | PubMed |
| 42597430 | Medical comorbidities of patients receiving amyloid-targeting treatments in a memory clinic. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42597430 | PubMed |
| 42565262 | Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42565262 | PubMed |
| 42535261 | Exploring longitudinal relationships among Alzheimer's disease biomarkers. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42535261 | PubMed |
| 42533677 | Classification of tau status with machine learning models in amyloid-positive cohorts. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42533677 | PubMed |
| 42507054 | Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study. | Jpn J Radiol | 2026 | https://conductscience.org/library/papers/42507054 | PubMed |
| 42505444 | Research Advances in Diagnostic Methods for Prevalent Neurological Diseases. | Biosensors (Basel) | 2026 | https://conductscience.org/library/papers/42505444 | PubMed |
| 42467182 | 18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers. | Ann Nucl Med | 2026 | https://conductscience.org/library/papers/42467182 | PubMed |
| 42458104 | Tau-mediated Mechanisms in Alzheimer's Disease Pathogenesis. | Mol Neurobiol | 2026 | https://conductscience.org/library/papers/42458104 | PubMed |
| 42453713 | Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment. | AIMS Neurosci | 2026 | https://conductscience.org/library/papers/42453713 | PubMed |
| 42436578 | A probabilistic framework for clinicopathological Alzheimer's disease using tau-PET. | Alzheimers Res Ther | 2026 | https://conductscience.org/library/papers/42436578 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39776249
GET https://conductscience.org/api/papers/v1/39776249/references?page=2